Sutetinib for Patients with Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase IIb Trial

Study limitation reported by the research below: “Sutetinib does not yet appear to have regulatory approval as of this paper's publication; clinical availability may be limited to trial or regional settings.”